Larry Ellberger Added to TransPharma Medical Board of Directors
LOD, Israel - TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, has appointed Larry Ellberger to the Company’s Board of Directors.
“We are pleased to welcome such an experienced and accomplished industry veteran to our Board. Larry brings with him over 30 years of experience in the life science and drug delivery industries. His broad strategic planning and corporate development expertise and high level relationships within the pharmaceutical industry will serve TransPharma well,” said Dr. Daphna Heffetz, Chief Executive Officer of TransPharma Medical Ltd. “We look forward to his counsel as TransPharma achieves important milestones this year, entering clinical trials for both our jointly developed hGH product with Teva and our in-house development of hPTH (1-34). Our ability to recruit someone of Larry’s stature to our team is a strong endorsement of the TransPharma business model and value proposition.”
Mr. Ellberger is a Founder and Principal of HVA, Inc. a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and medical device companies. He also is a member of the Board of Directors at Omrix Biopharmaceuticals, Inc., a NASDAQ-listed commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products. In addition, Mr. Ellberger is a Director at Avant Immunotherapeutics, a NASDAQ-listed vaccine biotechnology company.
Most recently, Mr. Ellberger held the position of Interim CEO of PDI, Inc., a sales and marketing service provider for pharmaceutical and biotech companies. Prior to that, he was Senior Vice President of Corporate Development and a member of the Board of Directors at PowderJect, a publicly-traded drug delivery company, which became one of the first profitable biotechnology companies in Europe following its IPO in 1997. Previously, Mr. Ellberger held several senior positions during his 20 year tenure at American Cyanamid Company, a leading life science company. He was also CFO and interim CEO at W.R. Grace & Co.
“I am delighted to join the board of TransPharma and look forward to contributing to the growth of its business. The combination of TransPharma’s unique transdermal drug delivery technology, together with its exceptional leadership team, offers its partners – current and future – significant added value in the development of innovative drug products,” commented Mr. Ellberger.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.